JASPER THERAPEUTICS, INC. Total Liabilities
JASPER THERAPEUTICS, INC. (JSPR) had Total Liabilities of $10.39 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-14
- 2026-06-30: Liabilities $10.39M.
- 2026-03-31: Liabilities $17.78M.
- 2025-12-31: Liabilities $31.63M.
- 2025-09-30: Liabilities $45.90M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $10.39M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $17.78M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $31.63M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $45.90M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $22.96M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $15.35M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $18.23M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $15.73M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $13.62M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $12.73M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $16.45M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $16.27M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $13.96M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $13.56M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $12.37M 10-K · filed 2024-03-05 | |
| 2022-09-30 | $11.54M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $11.59M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $12.44M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $24.14M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $28.61M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $14.26M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $11.10M 10-Q · filed 2021-05-24 | |
| 2020-12-31 | $14.65M 10-K · filed 2022-03-18 | $3.77M 10-K · filed 2021-03-30 |
| 2020-09-30 | $3.68M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $3.76M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $3.67M 10-Q · filed 2020-05-13 | |
| 2019-12-31 | $10.85M 10-K/A · filed 2021-05-24 | $3.61M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |